Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | RHOC | P08134 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin Lactone SCHEMBL13762456 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1258955 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1265 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL12648491 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL10025147 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL12060138 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL9810905 | 0.97 | HMGCR (0.94) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL5605464 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL13992376 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL5605468 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0687263-B1 | PROCESS FOR PREPARING (TRANS)-6- [2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS | WARNER LAMBERT CO (US) | 1997-07-30 | — | — | EP | claimed |
| EP-0330172-B1 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER LAMBERT CO (US) | 1994-08-10 | — | — | EP | claimed |
| EP-0448552-A1 | IMPROVED PROCESS FOR $i(TRANS)-6- 2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1991-10-02 | — | — | EP | claimed |
| US-5003080-A | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-03-26 | — | — | US | claimed |
| EP-0247633-B1 | Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)-alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-01-30 | — | — | EP | claimed |
| WO-1989007598-A2 | IMPROVED PROCESS FOR TRANS-6-[2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1989-08-24 | — | — | WO | claimed |
| US-4681893-A | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | claimed |
| US-9006282-B2 | Rosuvastatin and atorvastatin derivatives | REDX PHARMA LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20130303773-A1 | Rosuvastatin and Atorvastatin Derivatives | REDX PHARMA PLC (GB) | 2013-11-14 | — | — | US | disclosed |
| EP-2405910-B1 | Rosuvastatin and atorvastatin derivatives | REDX PHARMA LTD (GB) | 2013-09-04 | — | — | EP | disclosed |
| US-8513412-B2 | Rosuvastatin and atorvastatin derivatives | RedX Pharna Limited (GB) | 2013-08-20 | — | — | US | disclosed |
| EP-2614822-A2 | Atorvastatin Derivatives | Redx Pharma Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| EP-2405911-B1 | USE OF ATORVASTATIN LACTOLS AS MEDICAMENTS | REDX PHARMA LTD (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-5003080-A | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| EP-0247633-B1 | Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)-alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1991-01-30 | — | — | EP | disclosed |
| EP-0409281-A1 | (R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-01-23 | — | — | EP | disclosed |
| EP-0330172-A2 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0330172-A2 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0247633-A1 | Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)-alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-12-02 | — | — | EP | disclosed |
| US-4681893-A | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | WARNER-LAMBERT COMPANY (US) | 1987-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303773-A1 | Rosuvastatin and Atorvastatin Derivatives | HMGCR, PCSK9, SREBF1 | HMGCR 1/4885SLCO1B1 420/4885ABCB1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.